Autolus data show leukemia responses deepen beyond first month after obe-cel treatment

Bitget2026/11/04 14:17

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Autolus Therapeutics will present clinical updates at the American Society of Hematology meeting, December 12-15, 2026, in New Orleans.
Obe-cel responses deepened beyond the first month in relapsed or refractory adult B-cell leukemia; delayed responders had outcomes comparable to early responders.
Initial phase 1 ALARIC results showed complete blood responses in patients receiving D8 CAR-T for relapsed or refractory AL amyloidosis.
Treatment was well tolerated, with encouraging improvements in organ function.
A separate analysis supported a commercially available test for monitoring obe-cel levels in clinical practice.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autolus Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040915PRIMZONEFULLFEED9870030) on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Autolus data show leukemia responses deepen beyond first month after obe-cel treatment

You may also like

Crypto prices